Blood online
Home About Blood Authors Subscriptions Permission Advertising Public Access contact us
 

 
Advanced
Current Issue
First Edition
Future Articles
Archives
Submit to Blood
Search
American Society of Hematology
Meeting Abstracts
Email Alerts
This Article
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Right arrow Rights and Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via CrossRef
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Lubahn, B. C.
Right arrow Articles by Reisner, H. M.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Lubahn, B. C.
Right arrow Articles by Reisner, H. M.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati  
What's this?

arrow to previous article Previous Article  |  Table of Contents  |  Next Article next article arrow

Identification of a F.VIII epitope recognized by a human hemophilic inhibitor

BC Lubahn, J Ware, DW Stafford and HM Reisner

Department of Biology, University of North Carolina, Chapel Hill 27599.

Hemophilia A, one of the most common of the inherited bleeding disorders, results from a deficiency or abnormality of factor VIII (F.VIII). In approximately 15% of persons with hemophilia, treatment with exogenous F.VIII is complicated by the development of anti-F.VIII antibodies which block F.VIII coagulant activity. These antibodies have been termed inhibitors. To localize epitopes recognized by inhibitors, we used a lambda gt11 library which expresses small random fragments of F.VIII as fusion proteins. One epitope has been mapped to the 25-amino acid sequence lys-338 through asp-362 of F.VIII (E338-362). Immunoaffinity-purified antibodies that react with this epitope neutralize F.VIII:C activity. E338-362 is adjacent to an enzymatic cleavage site at arg-372 which is important in F.VIII activation. Hence, an antibody binding to E338-362 would probably block this cleavage and thereby block activation of F.VIII.

Volume 73, Issue 2, pp. 497-499, 02/01/1989
Copyright © 1989 by The American Society of Hematology


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati    What's this?


This article has been cited by other articles:


Home page
 J. Immunol.Home page
B. Wootla, S. Dasgupta, J. D. Dimitrov, J. Bayry, H. Levesque, J.-Y. Borg, A. Borel-Derlon, D. N. Rao, A. Friboulet, S. V. Kaveri, et al.
Factor VIII Hydrolysis Mediated by Anti-Factor VIII Autoantibodies in Acquired Hemophilia
J. Immunol., June 1, 2008; 180(11): 7714 - 7720.
[Abstract] [Full Text] [PDF]

Home page
 J. Immunol.Home page
S. Lacroix-Desmazes, B. Wootla, S. Dasgupta, S. Delignat, J. Bayry, J. Reinbolt, J. Hoebeke, E. Saenko, M. D. Kazatchkine, A. Friboulet, et al.
Catalytic IgG from Patients with Hemophilia A Inactivate Therapeutic Factor VIII
J. Immunol., July 15, 2006; 177(2): 1355 - 1363.
[Abstract] [Full Text] [PDF]

Home page
 NEJMHome page
S. Lacroix-Desmazes, J. Bayry, N. Misra, M. P. Horn, S. Villard, A. Pashov, N. Stieltjes, R. d'Oiron, J.-M. Saint-Remy, J. Hoebeke, et al.
The Prevalence of Proteolytic Antibodies against Factor VIII in Hemophilia A
N. Engl. J. Med., February 28, 2002; 346(9): 662 - 667.
[Abstract] [Full Text] [PDF]


click for free articles
home about blood authors subscriptions permissions advertising public access contact us
  Copyright © 1989 by American Society of Hematology         Online ISSN: 1528-0020